Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 16,542 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Connective Tissue Disease Clear all

Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Interventions: LY4052031, Pembrolizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 22
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 15 more

Conditions: Chemotherapy-induced Thrombocytopenia
Interventions: Romiplostim, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Ogden, Utah • Spokane, Washington

Conditions: Venous Hypertension Ulcers, Venous Stasis Ulcer, Venous Ulcer, Venous Insufficiency, Leg Ulcer, Foot Ulcer, Varicose Ulcer, Diabetic Foot
Interventions: Cooling gel pack, Cooling cotton pack; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 50 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Charleston, South Carolina • Spartanburg, South Carolina

Conditions: Rheumatoid Arthritis
Interventions: SAR153191 (REGN88); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 4
States / cities: Beverly Hills, California • Ocala, Florida • Duncansville, Pennsylvania + 1 more

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: Female only
Enrollment: 442 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Neuroblastoma
Interventions: Topotecan, Temozolomide, Ribociclib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Months to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Boston, Massachusetts • New Hyde Park, New York • Memphis, Tennessee

Conditions: Actinic Keratoses, Aging, Non-Melanoma Skin Cancer
Interventions: Fractionated Laser Resurfacing; Device
Lead sponsor: Wright State University; Other
Eligibility: 60 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Breast Cancer
Interventions: RAD 001; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Raynaud Disease, Raynaud Phenomenon, Raynaud Syndrome
Interventions: Blue Light Therapy, Sham Light Therapy; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Granuloma Annulare
Interventions: Abrocitinib 200 mg; Drug
Lead sponsor: William Damsky; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Psoriasis
Interventions: Cedirogant, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 31 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 3,280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Kirksville, Missouri

Conditions: Onychomycosis
Interventions: light therapy; Device
Lead sponsor: Nomir Medical Technologies; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Southborough, Massachusetts

Conditions: Hereditary Angioedema
Interventions: Icatibant, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 39
States / cities: Alabaster, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 35 more

Conditions: Breast Cancer
Interventions: breast imaging study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older · Female only
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sjogren Syndrome
Interventions: VAY736, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 23
States / cities: Fullerton, California • La Palma, California • Brandon, Florida + 19 more

Conditions: Breast Cancer
Interventions: docetaxel, paclitaxel, pertuzumab, pertuzumab-placebo, trastuzumab [Herceptin], trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 62
States / cities: Little Rock, Arkansas • La Jolla, California • Montebello, California + 55 more

Conditions: Lung Cancer, Ovarian Cancer, Breast Cancer, Hodgkin's Disease, Neuroblastoma
Interventions: Symptom Assessment Scale; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Angiogenesis
Interventions: Aspirin; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 95 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Triple Negative Breast Cancer, Breast Cancer
Interventions: Capecitabine; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Stanford, California

Conditions: Melanoma
Interventions: Vemurafenib; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Breast Cancer
Interventions: memory training, speed of processing training, waitlist control; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 40 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Squamous Cell Cancer, Squamous Cell Carcinoma, Skin Cancer, Non-melanoma Skin Cancer
Interventions: 30% ascorbic acid in DMSO; Drug
Lead sponsor: Center for Biomedical Research, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boise, Idaho

Conditions: Early Breast Cancer
Interventions: Giredestrant, Anastrozole, Palbociclib, Surgery; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Burbank, California • Laguna Hills, California • San Luis Obispo, California + 7 more

Search by objective public record fields.

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence

Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia

Trial of RAD001 in Triple Negative Metastatic Breast Cancer

Phototherapy For Treatment Of Raynaud's Phenomenon

Janus Kinase Inhibition in Granuloma Annulare

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

Remibrutinib in Real-world Clinical Practice

Using Light Therapy to Treat Toe Nail Fungus

A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)

Vibro-Acoustography Imaging in Diagnosing Breast Masses in Women With a Breast Mass or Breast Cancer

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers

The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases

Memory Training Intervention for Breast Cancer Survivors

Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)